Japan, South Korea, and China: which Asian origin approvals actually shorten Latin American device reviews

Asian device manufacturers keep asking me the same question in three different accents: if we already cleared Japan, Korea or China, which Latin American agencies will shorten the technical review? The honest answer is not "Asia equals fast track." Reliance in Latin America is authority-specific. A Japanese marketing authorization can open an abridged path in Brazil today. A Korean or Chinese authorization does not automatically do the same thing on the same form.

I'm Julio Martinez-Clark. I co-founded Amavita Sciences™ after years of putting device dossiers in front of Latin American regulators with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. This article maps what Japan (PMDA / MHLW), South Korea (MFDS) and China (NMPA) actually buy you in Brazil, Mexico and Colombia right now — and what still requires a full technical file in Spanish or Portuguese.

Reliance means a Latin American agency uses another regulator's assessment as the sole or complementary reference for its own decision. It does not mean rubber-stamp approval. The local agency still decides, still asks for local labeling and administrative annexes, and still rejects a file that is not essentially the same device.

Three instruments matter most for this comparison:

• Brazil — ANVISA Instrução Normativa (IN) 290 of 4 April 2024 (effective 3 June 2024), under RDC 741/2022: an optimized analysis procedure for Class III and IV devices and IVDs that takes advantage of assessments from listed Equivalent Foreign Regulatory Authorities (EFRAs).
• Mexico — COFEPRIS abbreviated / equivalency pathway (operational from 1 September 2025): a reliance route for devices that already hold authorization from recognized reference regulators, including IMDRF Management Committee members and full MDSAP participants, with a published decision target on complete files.
• Colombia — INVIMA: Colombia has joined IMDRF and is building optimized-analysis language into its device framework. Sponsors should confirm the current circular or decree text with counsel before treating any foreign certificate as an abridged trigger; do not assume Brazil's EFRA list copies into Bogotá.

IMDRF membership helps a manufacturer's story. It does not, by itself, put that manufacturer's home agency onto every Latin American reliance schedule.

Japan is the cleanest Asian origin for Brazil today. Article 6 of ANVISA IN 290/2024 lists four EFRAs and their evidence types. Japan appears as Japan Ministry of Health, Labour and Welfare (MHLW) pre-market approval (Shonin). The other three are Australia TGA (ARTG), Health Canada (Medical Device Licence), and U.S. FDA (510(k), PMA, or De Novo). Korea and China are not on that list.

For a Japanese-cleared Class III or IV device that is essentially identical — same intended use, same manufacturer, same essential characteristics — IN 290 lets ANVISA run an optimized review that uses the foreign assessment as reference. ANVISA can still switch the file back to ordinary review. The petitioner still files the Brazilian documentary package under RDC 751/2022 (or the IVD rules under RDC 830/2023), plus the IN 290 annex declaration, the apostilled or consularized foreign authorization with sworn Portuguese translation when required, and the instructions for use as approved in the reference jurisdiction.

What Amavita Sciences™ actually localizes for these files:

• Japanese marketing authorization and QMS evidence into Portuguese sworn or certified translations as the form demands.
• STED-style technical content mapped to ANVISA's Brazilian Portuguese labeling and IFU expectations.
• Term control so device name, intended use and numerical claims do not drift between the Shonin package and the Brazilian annexes.

Japan also sits inside IMDRF and MDSAP. That helps Mexico's abbreviated pathway, where IMDRF Management Committee and MDSAP authorities are in the recognition set. A Japanese clearance is therefore useful in more than one Latin American capital — but the dossier shape still changes by country.

South Korea's MFDS is an IMDRF member and, as of July 2026 reporting, was added to WHO's transitional list of medical-device regulators (tWLA). That is a meaningful signal of international regulatory maturity. It is not the same thing as appearing on ANVISA IN 290's EFRA list.

As of the published IN 290 text, MFDS is not one of the four EFRAs. A Korean manufacturer filing Class III or IV in Brazil should plan for ordinary ANVISA technical review unless and until ANVISA amends Article 6. Do not build a launch calendar on a future list change that has not been published.

Where Korea does help today:

• Mexico's abbreviated pathway can treat IMDRF Management Committee authorizations as reference inputs when the device is identical and the Spanish file is complete. MFDS membership in IMDRF is the relevant fact, not a bilateral "July 2026 LATAM fast track" slogan.
• MDSAP / ISO 13485 evidence still reduces redundant QMS friction even when the pre-market review itself is not abridged.
• Technical dossier quality from an MFDS review often transfers well into Spanish and Portuguese STED modules — if you protect terminology and numbers during localization.

What Korean teams should put in the master file before a Latin American wave: English or Korean source IFUs locked, a single termbase for device and indication language, QMS certificates ready for apostille, and a clear statement of whether the Latin American intended use matches the MFDS intended use exactly. Essential sameness is the gate that kills abbreviated hopes.

Chinese NMPA registration is a serious regulatory achievement. It is not, under ANVISA IN 290/2024, an EFRA trigger. Brazil's optimized list does not include NMPA. For high-risk Brazilian filings, expect ordinary technical evaluation: biocompatibility, electrical safety, risk management under ISO 14971, software documentation where applicable, and clinical evaluation materials in the form ANVISA requires.

Mexico's abbreviated framework is broader because it keys off IMDRF / MDSAP recognition sets rather than a four-name EFRA annex. Even there, COFEPRIS still requires a complete Spanish dossier, identity with the reference authorization, and local administrative instruments. NMPA paperwork does not replace Mexican labeling, Spanish IFUs or the Mexican registration holder structure.

Practical translation consequences for NMPA-origin files:

• Budget full Spanish (and Brazilian Portuguese for ANVISA) localization of IFUs, labels, clinical evaluation narratives and risk summaries.
• Keep laboratory annexes under control: some agencies accept original-language verification reports with a Spanish or Portuguese resumen; others want more. Scope that per country instead of translating every table by habit.
• Do not assume a Chinese clinical dataset will be read the same way in Latin America as a Japanese or U.S. dataset. Map the clinical evidence to each agency's expectations before you freeze the dossier.

Reliance shortens technical re-review. It does not delete the local language stack. Across Brazil, Mexico and Colombia you should still plan for:

• Local-language IFUs and labeling that match the claimed intended use.
• Sworn or certified translations of legal instruments (powers of attorney, free-sale certificates, authorizations) at the tier each agency demands.
• A controlled term list so the device name and indication language stay identical across Portuguese and Spanish country packs.
• Administrative annexes that only exist locally — registration-holder letters, importer designations, fee proofs, and platform uploads (including Mexico's DIGIPRIS workflows where they apply).

Amavita Sciences™ does not quote per-word rates for this work. Per-word billing pushes teams to translate pages that reliance pathways may not need in full, and to under-invest in the term control and medical review that actually prevent first-cycle observations. We scope by document role: what must be full local language, what can stay original with a summary, and what is a legal instrument that needs sworn treatment.

1. Origin = Japan (MHLW Shonin), target = Brazil Class III/IV: evaluate IN 290 optimized analysis first; prepare Portuguese package + EFRA evidence.
2. Origin = Korea or China, target = Brazil Class III/IV: plan ordinary ANVISA review until Article 6 changes; do not sell the board an abridged clock.
3. Origin = Japan, Korea or other IMDRF MC member, target = Mexico: evaluate COFEPRIS abbreviated / equivalency eligibility on sameness and Spanish completeness.
4. Any Asian origin, target = Colombia: confirm INVIMA's current reliance or optimized-analysis instruments case by case; default to a complete Spanish technical story.
5. Every path: lock one master technical dossier, then localize annexes — the subject of our parallel twelve-country localization work.

Japan is the Asian origin that currently lines up cleanly with Brazil's published EFRA list. Korea's July 2026 WHO tWLA recognition improves the credibility narrative and can support IMDRF-keyed pathways such as Mexico's abbreviated route; it does not rewrite IN 290. China still means a full technical localization plan for Brazil and a careful, country-by-country read elsewhere.

Explore Amavita Sciences™ regulatory translation and Latin American technical dossier adaptation at amavitasciences.com when you are ready to map an origin authorization to the agencies you will actually file.